ELIZABETH PRINGLE introduced by DR. MARY WILMERS (London). 'A Study of 112 Children with Coeliac
Disease from 1950-69.' (To be published elsewhere.) E. RossIPAL (Graz). 'Precipitins to Aqueous Extracts of Flour in Coeliac Disease.' In certain instances it may be difficult to differentiate between coeliac disease and the 'coeliac syndrome'. An essential diagnostic criterion in coeliac disease is the disappearance of symptoms on a gluten-free diet, and a relapse caused by reintroduction of gluten into the diet. Normally a long period of observation is necessary to confirm the diagnosis in this way. We have been able to develop a sensitive method of detecting precipitins to aqueous and alcoholic extracts of flour from wheat, barley, oats, and rye in the serum of patients with coeliac disease in 15 patients. The diagnosis of coeliac disease was confirmed by disappearance of the symptoms on a gluten-free diet and by a relapse after reintroduction of gluten into the diet. All of these patients had precipitating antibodies to aqueous extracts of wheat and barley; 13 also showed precipitins to extracts of oats, and 10 to extracts of rye. It was proved that the precipitating antibodies to the aqueous extracts of flour belonged to the IgG group. Sera of 60 children suffering from parenteral diarrhoea, Esch. coli enteritis, disaccharide intolerance, and mucoviscidosis, and pooled serum of 100 healthy adult blood donors all served as controls. In none of these controls could precipitins to aqueous extracts of the cereals be detected. The Medical Research Council Working Party on Embryonal Tumours in Childhood (Chairman Professor R. S. Illingworth) is currently planning two therapeutic trials in Wilms' tumour (nephroblastoma) and neuroblastoma.
The trial of treatment in nephroblastoma is designed to assess the relative efficacy of vincristine and actinomycin D as agents in the treatment of nephroblastoma following surgery and radiotherapy. There is now increasing evidence that the prognosis of nephroblastoma is improved by the use of actinomycin D for periods of two years following surgery and radiotherapy. There is also evidence that vincristine, a drug which is somewhat less toxic than actinomycin D, is efficacious in treating metastatic disease. It is therefore planned to conduct a controlled clinical trial in children over the age of 1 year with Stage I, IIA, and IIB (American classification) disease.
The trial of treatment of neuroblastoma is designed to investigate whether the regression that sometimes occurs in this disease is a consequence of an immune reaction developed against the tumour and if so whether this immunity can be increased by immunotherapy. There is experimental evidence that neuroblastomas contain tumour specific antigens against which an immune reaction may be stimulated, and also that the immune system is more likely to succeed in eradicating a tumour when the number of residual malignant cells in the body is low. It is therefore important that immunotherapy should follow a period of chemotherapy, and in this trial it is proposed to treat patients with vincristine and cyclophosphamide for this purpose. The Working Party considered that the most suitable group of patients for such a trial are as follows.
(1) All patients over the age of 1 year with neuroblastoma, except those with a primary lesion confined to the cervical region.
(2) All children under the age of 1 year with metastatic disease.
Owing to the rarity of these tumours and the importance of obtaining information on the best methods of treatment with reasonable speed, it is hoped that suitable cases will be notified to the secretaries of the Working Party:-Dr. P. Morris Jones and Dr. Dorothy Pearson (at The Royal Manchester Children's Hospital, Pendlebury, Manchester. M27 1HA), from whom further information and detailed protocols may be obtained. 
